AstraZeneca PLC News
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc, as well as research collaboration with Sernova Corp. to evaluate novel potential therapeutic cell applications. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
see moreAstraZeneca PLC Market News
11d
AstraZeneca Invests $2 Billion in Summit Therapeutics to Advance Novel ADC–Bispecific Antibody Cancer Combo
- AstraZeneca has committed $2 bn to Summit Therapeutics and launched a clinical collaboration to test novel ADC and bispecific combo in gastrointestinal cancers.
25d
AstraZeneca Scores Dual Wins: U.S. Accelerated Approval for Etcamah and Imfinzi Combo Survival Boost
In the past week, AstraZeneca (AZN) secured FDA accelerated approval for Etcamah combo and reported survival gains from its Imfinzi plus Imdelltra regimen.
06 Sep at 10:17
AstraZeneca Secures Multiple Regulatory Wins in Early September as Cancer and Lung Drug Programs Advance
AstraZeneca clinches EU approval for Enhertu combo, inks global licensing for Zegfrovy, and wins US approval for Etcamah combo—marked strides in oncology and respiratory pipelines.
23 Aug at 10:17
AstraZeneca Halts eVOLVE‑Lung02 Phase III Trial in mNSCLC Patients After IDMC Review
AstraZeneca has discontinued its Phase III eVOLVE‑Lung02 trial of volrustomig with chemotherapy in metastatic NSCLC, following recommendation by the Independent Data Monitoring Committee.
02 Aug at 02:46
AstraZeneca's Wainua Trial Failure Results in £20 Billion Market Value Loss
AstraZeneca's stock experienced a notable decline following the announcement that its Phase III trial for Wainua (eplontersen), a drug developed in partnership with Ionis Pharmaceuticals, failed to meet its primary efficacy endpoint. The trial aimed to assess Wainua's effectiveness in reducing cardiovascular deaths and recurrent cardiovascular events in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). The results showed no statistically significant benefit over placebo when added to standard care. ([ca.investing.com](https://ca.investing.com/news/stock-market-news/why-is-astrazeneca-stock-plunging-today-93CH-4726435?utm_source=openai))
26 Jul at 19:38
AstraZeneca Faces Major Setback as Wainua Heart Drug Fails Phase III Trial
On July 9, 2026, AstraZeneca announced that its experimental heart drug, Wainua (eplontersen), failed to meet the primary efficacy endpoint in the Phase III CARDIO-TTRansform trial. This unexpected outcome led to a substantial decline in the company's stock price, with shares dropping 9.55% in a single day, erasing approximately £19 billion from its market value.
